Back to 
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
SYRE
3 quarters
Position history for RA CAPITAL MANAGEMENT, L.P.'s holdings in SPYRE THERAPEUTICS INC
No. RA Capital Management exited its SYRE (Spyre Therapeutics) position in Q2 2026. Its Q1 2026 13F listed 1,621,620 shares worth $81.8M. RA Capital Management first reported SYRE in Q4 2025 and held it in 2 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
-$53.1M
Total Shares Change
-1.6M
Quarter-by-Quarter History